• Policy
• Once-weekly growth hormone Sogroya is approved in Korea
• by Lee, Hye-Kyung Mar 7, 2024 07:16am

• Policy
• The RSA track to include drugs for chronic diseases, asthma
• by Lee, Tak-Sun Mar 7, 2024 07:15am

• Policy
• Will Ferinject be reimbursed this time?
• by Lee, Tak-Sun Mar 5, 2024 05:48am

• Policy
• Guideline to be revised to prevent unintentional impurities
• by Lee, Hye-Kyung Mar 4, 2024 05:52am

• Policy
• Will the novel anticancer drug Enhertu be reimb in April?
• by Lee, Tak-Sun Mar 4, 2024 05:52am

• Policy
• Patients bear 100% of Imfinzi cost for biliary tract cancer
• by Lee, Tak-Sun Feb 28, 2024 05:50am

• Policy
• AbbVie Korea will discontinue supply of Kaletra
• by Lee, Tak-Sun Feb 27, 2024 05:45am

• Policy
• Expedited domestic supply of suspended essential medicines
• by Lee, Hye-Kyung Feb 27, 2024 05:45am

• Policy
• Delayed actual transaction price cuts slash expected savings
• by Lee, Tak-Sun Feb 26, 2024 05:25am

• Policy
• Competition intensifies in 3-combo drug mkt for COPD·asthma
• by Lee, Tak-Sun Feb 23, 2024 05:48am